 Proprotein Convertases
"Proprotein Convertases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteolytic enzymes that are involved in the conversion of protein precursors such as peptide prohormones into PEPTIDE HORMONES. Some are ENDOPEPTIDASES, some are EXOPEPTIDASES.
| Descriptor ID |
D043484
|
| MeSH Number(s) |
D08.811.277.656.837
|
| Concept/Terms |
Proprotein Convertases- Proprotein Convertases
- Convertases, Proprotein
- Proprotein Convertase
- Convertase, Proprotein
Prohormone Convertases- Prohormone Convertases
- Convertases, Prohormone
- Prohormone Convertase
- Convertase, Prohormone
Subtilisin-Like Proprotein Convertases- Subtilisin-Like Proprotein Convertases
- Convertases, Subtilisin-Like Proprotein
- Proprotein Convertases, Subtilisin-Like
- Subtilisin Like Proprotein Convertases
Pro-Opiomelanocortin Converting Enzyme- Pro-Opiomelanocortin Converting Enzyme
- Converting Enzyme, Pro-Opiomelanocortin
- Pro Opiomelanocortin Converting Enzyme
- POMC Enzyme
- Proopiomelanocortin Convertase
- Convertase, Proopiomelanocortin
- Pro-Opiocortin Converting Enzyme
- Converting Enzyme, Pro-Opiocortin
- Pro Opiocortin Converting Enzyme
- Pro-Opiocortin Converting Protease
- Converting Protease, Pro-Opiocortin
- Pro Opiocortin Converting Protease
- POMC Convertase
- Convertase, POMC
- POMC-Converting Enzyme
- POMC Converting Enzyme
|
Below are MeSH descriptors whose meaning is more general than "Proprotein Convertases".
Below are MeSH descriptors whose meaning is more specific than "Proprotein Convertases".
This graph shows the total number of publications written about "Proprotein Convertases" by people in this website by year, and whether "Proprotein Convertases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 | | 1992 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 1994 | 1 | 1 | 2 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 2 | 2 | | 1998 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 2 | 1 | 3 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proprotein Convertases" by people in Profiles.
-
Stein EA. PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all : Editorial to: "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher" by Henry N. Ginsberg et Al. Cardiovasc Drugs Ther. 2016 10; 30(5):427-431.
-
Dong X, Chiu H, Park YJ, Zou W, Zou Y, Özkan E, Chang C, Shen K. Precise regulation of the guidance receptor DMA-1 by KPC-1/Furin instructs dendritic branching decisions. Elife. 2016 Mar 14; 5.
-
Walley KR, Francis GA, Opal SM, Stein EA, Russell JA, Boyd JH. The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. Am J Respir Crit Care Med. 2015 Dec 01; 192(11):1275-86.
-
Stein EA, Raal FJ. Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
-
Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015 Oct 27; 132(17):1648-66.
-
Butkinaree C, Canuel M, Essalmani R, Poirier S, Benjannet S, Asselin MC, Roubtsova A, Hamelin J, Marcinkiewicz J, Chamberland A, Guillemot J, Mayer G, Sisodia SS, Jacob Y, Prat A, Seidah NG. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem. 2015 Jul 24; 290(30):18609-20.
-
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 01; 36(17):1012-22.
-
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
-
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
-
Blom DJ, Wasserman SM, Stein EA. Evolocumab in hyperlipidemia. N Engl J Med. 2014 08 28; 371(9):877-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|